We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Directional DBS of the Fornix in Alzheimer's Disease Achieves Long-Term Benefits: A Case Report.
- Authors
Barcia, Juan A.; Viloria, María Aurora; Yubero, Raquel; Sanchez-Sanchez-Rojas, Leyre; López, Amanda; Strange, Bryan Andrew; Cabrera, María; Canuet, Leonides; Gil, Pedro; Nombela, Cristina
- Abstract
Background: Current treatments for Alzheimer's disease (AD) modulate global neurotransmission but are neither specific nor anatomically directed. Tailored stimulation of target nuclei will increase treatment efficacy while reducing side effects. We report the results of the first directional deep brain stimulation (dDBS) surgery and treatment of a patient with AD in an attempt to slow the progression of the disease in a woman with multi-domain, amnestic cognitive status. Methods: We aimed to assess the safety of dDBS in patients with AD using the fornix as stimulation target (primary objective) and the clinical impact of the stimulation (secondary objective). In a registered clinical trial, a female patient aged 81 years with a 2-year history of cognitive decline and diagnoses of AD underwent a bilateral dDBS surgery targeting the fornix. Stimulation parameters were set between 3.9 and 7.5 mA, 90 μs, 130 Hz for 24 months, controlling stimulation effects by 18F-fluoro-2-deoxy-D-glucose (18F-FDG) scans (baseline, 12 and 24 months), magnetoencephalography (MEG) and clinical/neuropsychological assessment (baseline, 6, 12, 18, and 24 months). Results: There were no important complications related to the procedure. In general terms, the patient showed cognitive fluctuations over the period, related to attention and executive function patterns, with no meaningful changes in any other cognitive functions, as is shown in the clinical dementia rating scale (CDR = 1) scores over the 24 months. Such stability in neuropsychological scores corresponds to the stability of the brain metabolic function, seen in PET scans. The MEG studies described low functional connectivity at baseline and a subsequent increase in the number of significant connections, mainly in the theta band, at 12 months. Conclusion: The dDBS stimulation in the fornix seems to be a safe treatment for patients in the first stage of AD. Effects on cognition seem to be mild to moderate during the first months of stimulation and return to baseline levels after 24 months, except for verbal fluency. Clinical Trial Registration: [https://clinicaltrials.gov/ct2/show/NCT03290274], identifier [NCT03290274].
- Subjects
DEEP brain stimulation; DISEASE progression; SAFETY; EXECUTIVE function; ALZHEIMER'S disease; BRAIN surgery; TREATMENT effectiveness; RANDOMIZED controlled trials; NEUROPSYCHOLOGICAL tests; PRE-tests &; post-tests; RADIOPHARMACEUTICALS; POSITRON emission tomography; DEOXY sugars; STATISTICAL sampling; LONG-term health care; WOMEN'S health; NEUROLOGIC examination; EVALUATION
- Publication
Frontiers in Aging Neuroscience, 2022, Vol 14, p1
- ISSN
1663-4365
- Publication type
Article
- DOI
10.3389/fnagi.2022.809972